Navigation Links
Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
Date:4/8/2008

- Agreement includes upfront, milestone and royalty payments on future

sales -

TORONTO, April 8 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company dedicated to the research and development of pharmaceutical products and technologies for the management of cancer, announced today that its subsidiary GeneSense Technologies, Inc. ("GeneSense") has signed an exclusive multinational license agreement with Zor Pharmaceuticals LLC formed as a subsidiary of Zoticon Bioventures Inc. ("Zoticon"), a research-driven biopharmaceutical group, to further develop and commercialize Virulizin(R) for human therapeutic applications. The initial clinical development of Virulizin(R) under the agreement will be in advanced pancreatic cancer.

Under the terms of the agreement, GeneSense will be entitled to receive payments in excess of US$10 million upon achievement of various milestone events and royalties that vary from 10-20% depending on achieving of sales of Virulizin(R) and subject to certain other adjustments. In addition, a wholly owned subsidiary of Lorus, Pharma Immune Inc. ("Pharma Immune") will receive 25% of the initial equity in Zor Pharmaceuticals. Pharma Immune's equity will not be subject to dilution on the first US$5 million of financing in Zor Pharmaceuticals. Thereafter, Pharma Immune has, at its option, a right to participate in any additional financings to maintain its ownership level. In addition, GeneSense has entered into a Service Agreement with Zor Pharmaceuticals to assist in the transfer of knowledge and establish a strong foundation for moving forward with the development program for Virulizin.

Zor Pharmaceuticals will be responsible for the cost of all the clinical development, regulatory submissions and commercialization of Virulizin(R) in North and South America and Europe. GeneSense will retain rights in all other countries, including Jap
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Billerica, Massachusetts (PRWEB) November 24, 2014 ... Simplify Panels ” from METTLER TOLEDO demonstrates how ... panel. , Power analytics and sample panel design ... control cycle chemistry and protect against corrosion and ... take up a significant amount of panel space. ...
(Date:11/24/2014)... , November 24, 2014 ... Workflow, honored for dynamic leadership skills, business acumen ... technical and medical information products and services, congratulates ... for Clinical Reference and Workflow, Elsevier Clinical Solutions, for ... Worth Watching ® Awards issue of Profiles ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Two new educational ... what comes next for ALS research and how the pharmaceutical ... After the Ice Bucket Challenge: Where Does the ALS Money ... Tuesday, 2 December 2014, Time: 1:30pm ET, Register ... expert speaker Dr. Merit Cudkowicz, Julianne Dorn Professor of Neurology ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 Prominent ... investors will gather on December 3rd at Genetic ... Conferences series. GeneticRx will take place at the ... School and will discuss the present and future ... exon skipping, and gene editing—as well as the ...
Breaking Biology Technology:New Video Shows How to Simplify Cycle Chemistry Sample Panels to Save Time and Costs 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2
... IRVINE, Calif., Oct. 15 The increased emphasis ... more costly medical,product development programs and requires rapid, ... appropriately. Expertise,to effect constructive change can be found ... protect our clients from compliance errors,that can lead ...
... from the Swedish medical university Karolinska Institutet reveals completely ... that contradict previous findings. The studies, which are published ... that hair follicle stem cells can divide actively and ... "The stem cells don,t behave at all in the ...
... Vineland Research and Innovation,Centre, an independent, not-for-profit ... horticultural science and innovation in Ontario,today announced ... the new role of,Research Chair, Molecular Breeding ... is determined to become a beacon of ...
Cached Biology Technology:Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 2Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services 3Vineland Welcomes Dr. Daryl Somers as Research Chair, Molecular Breeding and Biotechnology 2
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
(Date:11/7/2014)... , November 6, 2014 Leading Biometric ... better mobile security revolutionizing online transactions.  Companies in focus today ... Ltd. (NYSE: BABA ), Google Inc. (NASDAQ: ... eBay Inc. (NASDAQ: EBAY ) and MasterCard Inc. ... and NXTDW), a biometric authentication company focused on the ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... The Australian Imaging, Biomarker and Lifestyle Flagship Study of ... agreement with a major strategic alliance partner, Pfizer Australia., ... and aims to better understand the causes of Alzheimer,s ... The study is an initiative of the CSIRO ...
... CREEK, Calif. Diatoms, mighty microscopic algae, have profound influence ... breathe by capturing atmospheric carbon and in so doing, ... these photosynthetic wonders have come to acquire advantageous genes ... thrive in today,s oceans. These findings, based ...
... Ulrike Gaul, professor of molecular biology at Rockefeller ... theoretical physics at New York University and at ... first Alexander von Humboldt professorships ever to be ... for this distinction, and both applications were selected ...
Cached Biology News:Alzheimer's disease research attracts first partner 2Diatom genome helps explain success in trapping excess carbon in oceans 2Diatom genome helps explain success in trapping excess carbon in oceans 32 Alexander von Humboldt professorships go to LMU Munich 22 Alexander von Humboldt professorships go to LMU Munich 32 Alexander von Humboldt professorships go to LMU Munich 42 Alexander von Humboldt professorships go to LMU Munich 5
... in Molecular Probes. SlowFadeAntifade Kits is ... as a free radical scavenger that ... SlowFade formulation (S-2828) was designed to ... to almost zero (Figure 1); it ...
b6-2A12...
... prepared with pure chemicals according to our ... is designed to isolating intact and active ... One kit is consisted of reagents enough ... 10 20 g tissue or from ...
... EVOlyzer is Tecans new Enzyme-Linked Immunosorbent Assay ... Freedom EVOlyzer is a dedicated EVO platform ... reader, washer and incubation units operated by ... EVOlyzer is available in three sizes - ...
Biology Products: